^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colorectal Adenocarcinoma

    Related cancers:
    23h
    Multiomic analysis of colorectal adenocarcinoma reveals a new subtype of myofibroblastic cancer-associated fibroblasts that express high levels of B7-H3 and have poor-prognosis value. (PubMed, J Immunother Cancer)
    We suggest that anti-B7-H3 immunotherapies might preferentially target cells from the microenvironment rather than tumor cells. This is particularly important for understanding the mode of action of the anti-B7-H3 antibody‒drug conjugate, which is currently being tested in clinical trials in several solid tumors.
    Journal • IO biomarker
    |
    CD276 (CD276 Molecule)
    1d
    A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation (PubMed, Zhongguo Fei Ai Za Zhi)
    The patient showed no meaningful response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including the first-generation (Icotinib), the second-generation (Afatinib) and the third-generation (Aumolertinib). Trophoblast cell surface antigen 2-antibody-drug conjugate (TROP2-ADC) and immune checkpoint inhibitors (ICIs) combined with Bevacizumab also resulted in limited efficacy. Based on the clinical features and treatment response of this case, we reviewed the published literature about the pathological characteristics, mutational landscape, and current therapeutic approaches for PEAC, with a particular focus on the therapeutic challenges and future research directions for EGFR-mutant PEAC, aiming to provide insights for clinical practice and further studies..
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • EGFR exon 19 deletion
    |
    Avastin (bevacizumab) • Gilotrif (afatinib) • Conmana (icotinib) • Ameile (aumolertinib)
    2d
    A Study of Tucatinib and Trastuzumab in People With Rectal Cancer (clinicaltrials.gov)
    P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Herceptin (trastuzumab) • Tukysa (tucatinib)
    3d
    Crystal structures, cytotoxicity studies and interactions with DNA of novel in situ-formed complexes containing N-scorpionate ligands and nitrate ions. (PubMed, Acta Crystallogr C Struct Chem)
    The results show that complex 2 combines high anticancer potency with selective action towards colorectal adenocarcinoma cells and is more effective than complex 3 and the anticancer drug cisplatin. These properties make complex 2 an interesting candidate for further investigation of specific anticancer mechanisms.
    Journal
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    cisplatin
    3d
    Clinical study on the safety and efficacy of sintilimab combined with chemotherapy in neoadjuvant treatment of locally advanced rectal cancer (ChiCTR2500114358)
    P=N/A, N=41, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    3d
    Clinical study on the efficacy difference of regorafenib combined with sintilimab in the later-line treatment of left and right-sided colorectal cancer (ChiCTR2500109899)
    P4, N=60, Not yet recruiting, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital
    New P4 trial
    |
    Tyvyt (sintilimab) • Stivarga (regorafenib)
    4d
    A Retrospective Study of the Correlation Between Next-Generation Sequencing and Immunohistochemical Detection of TP53 in Colorectal Cancer. (PubMed, Technol Cancer Res Treat)
    Strong p53 expression (>55%) correlated closely with TP53 missense mutations, supporting IHC as a reliable surrogate. However, cases showing loss of p53 expression should undergo gene sequencing to confirm mutation status.
    Retrospective data • Journal • Next-generation sequencing
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    4d
    The Senescence-SASP Landscape in Colon Adenocarcinoma: Prognostic and Therapeutic Implications. (PubMed, Curr Issues Mol Biol)
    Our findings suggest CSRS score and its constituent genes represent potential biomarkers for prognosis and immunotherapeutic benefit in COAD patients. Extending this nine-gene set into a broader senescence-associated panel should be a next step toward delivering truly individualized treatment plans.
    Journal • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SERPINE1 (Serpin Family E Member 1) • FOXD1 (Forkhead Box D1) • PHGDH (Phosphoglycerate Dehydrogenase) • SNAI1 (Snail Family Transcriptional Repressor 1)
    5d
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, M.D. Anderson Cancer Center | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    6d
    ENCODE: Early Onset Colorectal Cancer Detection (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Liquid biopsy
    6d
    Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=39, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Stivarga (regorafenib)
    6d
    Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Aug 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)